fashion -WSS

fashion

author：leisure time 2025-10-02 18:49:02 - browse：5

Frank Pallone -- health policy coverage from STAT — Rep. Frank Pallone (D-N.J.) J. Scott Applewhite/AP

WASHINGTON — A Democrat has signed on to a legislative package that would require health care transparency by law and enact modest payment reforms to pharmacy middlemen and hospitals, increasing its chances of passing the House of Representatives.

Republicans conceded to a few tweaks to the legislation to ensure that transparency regulations for hospitals were at least equal to current regulations, which gained the endorsement of House Energy and Commerce Committee ranking member Frank Pallone (D-N.J.).

Two other prominent Democrats on relevant committees didn’t sign on: Rep. Richard Neal (D-Mass.), who had voiced concerns about the bill’s lack of transparency provisions requiring disclosure of private equity ownership, and Rep. Bobby Scott (D-Va.).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： UnitedHealth, Optum discontinue NaviHealth name

WSS

Roivant's CEO is a star, but biotech's black hole persists

Roche drug slashes death risk in early

Roivant's CEO is a star, but biotech's black hole persists

Study points to new risk in gene therapy death of Terry Horgan

UnitedHealth, Optum discontinue NaviHealth name

Lawsuit highlights wrinkle for disputes over surprise medical bills

hotspot

fashion

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

WHO recommends second malaria vaccine

Novavax promises a turnaround & Lilly roils the obesity market

Congress extends some pandemic preparedness programs

Cancer drug shortages should be causing more outrage

Cassava Sciences’ Alzheimer’s clinical trials should be halted

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CZI to create biohub to build anti

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

Smaller biotechs seek to piggyback on weight loss drug boom

Roche drug slashes death risk in early

Health insurers' Q3 question: how much care are people getting?

ADCs take center stage as promising cancer treatments

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Smaller biotechs seek to piggyback on weight loss drug boom

entertainment

entertainment

hotspot

leisure time